Please use this identifier to cite or link to this item: 10.3390/cancers15112957
Title: Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients
Authors: Berga-Švītiņa, Egija
Maksimenko, Jeļena
Miklaševičs, Edvīns
Fischer, Krista
Vilne, Baiba
Mägi, Reedik
Bioinformatics Group
RSU Institute of Oncology
Department of Biology and Microbiology
Keywords: BRCA1 pathogenic variant carriers;breast cancer;ovarian cancer;polygenic risk score (PRS);3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Oncology;Cancer Research;SDG 3 - Good Health and Well-being
Issue Date: Jan-2023
Citation: Berga-Švītiņa , E , Maksimenko , J , Miklaševičs , E , Fischer , K , Vilne , B & Mägi , R 2023 , ' Polygenic Risk Score Predicts Modified Risk in BRCA1 Pathogenic Variant c.4035del and c.5266dup Carriers in Breast Cancer Patients ' , Cancers , vol. 15 , no. 11 , 2957 . https://doi.org/10.3390/cancers15112957
Abstract: The aim of this study was to assess the power of the polygenic risk score (PRS) in estimating the overall genetic risk of women carrying germline BRCA1 pathogenic variants (PVs) c.4035del or c.5266dup to develop breast (BC) or ovarian cancer (OC) due to additional genetic variations. In this study, PRSs previously developed from two joint models using summary statistics of age-at-onset (BayesW model) and case–control data (BayesRR-RC model) from a genome-wide association analysis (GWAS) were applied to 406 germline BRCA1 PV (c.4035del or c.5266dup) carriers affected by BC or OC, compared with unaffected individuals. A binomial logistic regression model was used to assess the association of PRS with BC or OC development risk. We observed that the best-fitting BayesW PRS model effectively predicted the individual’s BC risk (OR = 1.37; 95% CI = 1.03–1.81, p = 0.02905 with AUC = 0.759). However, none of the applied PRS models was a good predictor of OC risk. The best-fitted PRS model (BayesW) contributed to assessing the risk of developing BC for germline BRCA1 PV (c.4035del or c.5266dup) carriers and may facilitate more precise and timely patient stratification and decision-making to improve the current BC treatment or even prevention strategies.
Description: Funding Information: This research has been developed with financing from the European Social Fund and Latvian state budget within the project no. 8.2.2.0/20/I/004 “Support for involving doctoral students in scientific research and studies” at Rīga Stradiņš University. Publisher Copyright: © 2023 by the authors.
DOI: 10.3390/cancers15112957
ISSN: 2072-6694
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.